Introduction {#S1}
============

RNA splicing is the process by which the spliceosome, a large ribonucleoprotein complex, catalyzes the excision of introns (non-coding regions) and the ligation of exons (coding regions) to form precursor-mRNAs (pre-mRNAs). After splicing and 5′- and 3′-end processing, pre-mRNAs become mature mRNAs that can be translated into functional proteins. Alternative splicing diversifies pre-mRNAs by varying which splice sites are used, resulting in events such as cassette exon skipping and intron retention. Alternative splicing generates unique transcripts from the same gene, creating isoforms with altered stability, localization, translation competency or coding sequence ([@B28]; [@B38]). RNA-binding proteins (RBPs) modulate alternative splicing by interacting with the spliceosome and binding to *cis* RNA elements to regulate splice site usage ([@B31]; [@B39]). The tissue specific expression and dynamic post-translational modification of RBPs ([@B21]; [@B22]; [@B29]) work together with epigenetic modifications to regulate alternative splicing patterns throughout development and in response to extracellular cues ([@B50]; [@B29]; [@B1]). In the brain, alternative splicing of neurotransmitter receptors and synaptic strength modulators is often regulated by activity, or neurotransmitter stimulation of synapses ([@B38]). However, little is known about the regulation and function of individual alternative splicing events.

Apolipoprotein E receptor 2 (apoER2), gene name *lrp8*, is a type I transmembrane protein of the low density lipoprotein receptor (LDLR) family. ApoER2 regulates cortical lamination during development ([@B49]), interneuron precursor migration in the rostral migratory stream ([@B2]) and learning and memory in the adult brain ([@B4]; [@B8]). Compared to other LDLR family members, apoER2 is enriched in the brain and displays an unusually high number of alternative splicing events ([@B32]; [@B9]), particularly within neurons ([@B55]). ApoER2 alternative splicing is enriched in cassette exon splicing events, in which entire exons are included or excluded from pre-mRNAs. To date, alternative splicing of apoER2 exons has been shown to modify ligand binding properties ([@B5]), receptor glycosylation and processing ([@B51]) and downstream signaling ([@B3]). Additionally, altered apoER2 alternative splicing has been implicated in sporadic Alzheimer's disease (sAD) ([@B25]), the most common form of dementia. ApoER2 binds the secreted lipid carrier apolipoprotein E (apoE) ([@B32]), of which the ε4 allele is the strongest genetic risk factor for sAD ([@B10]; [@B16]). However, how apoER2 alternative splicing becomes altered in sAD and whether altered apoER2 alternative splicing impacts its binding to apoE is unknown.

Whereas many reviews have focused on apoER2 function in brain development and adult synaptic plasticity ([@B44]; [@B27]; [@B37]), this mini-review will describe apoER2 structure and known function and regulation of apoER2 splice variants in the brain. We will also highlight key questions for future studies investigating apoER2 alternative splicing.

ApoER2 Structure {#S2}
================

Apolipoprotein E receptor 2 structure (reviewed in [@B12]) is modular, and individual exons tend to encode discrete functional domains ([Figure 1](#F1){ref-type="fig"}). ApoER2 contains five functional domains characteristic of the LDLR family. The N-terminal domain contains two types of binding repeats: LDL receptor type A (LDLa) and epidermal growth factor (EGF) precursor-like repeats. While mouse apoER2 contains eight LDLa repeats, analysis of the human *LRP8* gene suggests the exon encoding the eighth LDLa repeat was lost through exon shuffling ([@B34]). Therefore in mice, exon numbering is shifted compared to humans ([@B6]).

![ApoER2 Exon Structure and Protein Functional Domains. **(A)** Murine apoER2 protein structure with corresponding exon boundaries (dashed lines) and protein domains functionally annotated. The eighth LDLa repeat (highlighted in dark blue) is unique to mice. Open Reading Frame (ORF) window indicates number of nucleotides at the 3′ end of each exon that require nucleotides from the next exon to encode an amino acid in the correct ORF. **(B)** Human APOER2 structure.](fnmol-13-00144-g001){#F1}

The second functional domain is the β-propeller domain ([@B45]) followed by an O-linked glycosylation domain ([@B32]; [@B51]) and a hydrophobic transmembrane region. The fifth domain is a short cytoplasmic tail consisting of a conserved endocytic motif and a 59 amino acid insert that is not present in other LDLR family members ([@B32]; [@B42]; [@B6]; [@B41]).

APOER2 Splice Variants: Function and Regulation {#S3}
===============================================

Below we discuss what is known regarding function, expression and regulation of each apoER2 alternative splicing event ([Table 1](#T1){ref-type="table"}).

###### 

Summary of apoER2 alternatively spliced exons, including their associated *in vitro* and *in vivo* phenotypes, spatiotemporal distribution and known splicing regulators.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Alternative Exon          Functional domain affected                                 *In vitro* phenotype                                                                                                              *In vivo* phenotype                                                                       Spatiotemporal distribution                                                                                                                                Splicing regulator                Associated publications
  ------------------------- ---------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------- -------------------------------------------------------------
  Murine and Human exon 5   LDLa ligand binding repeats 4--6                           Required for α~2~-macroglobulin binding (HEK-293 cells)                                                                           Unknown                                                                                   **Murine**:\                                                                                                                                               Unknown                           [@B33]; [@B9]; [@B5]
                                                                                                                                                                                                                                                                                                                   -- solely Δex5 detected (total brain RNA)\                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                   **Human**:\                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                   -- +/Δex5 detected (total brain RNA)\                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                   -- solely Δex5 detected in adult frontal cortex, hippocampus and cerebellum and fetal brain (RNA)\                                                                                           

  Murine exon 7             LDLa ligand binding repeat 8 (lacking in humans)           -- Exclusion leads to lower affinity for β-VLDL particles (HEK-293 cells)\                                                        Unknown                                                                                   -- +/Δex7 both detected (total brain RNA)\                                                                                                                 Unknown                           [@B6], [@B5]; [@B34]; [@B35]; [@B24]
                                                                                       -- Exclusion confers altered affinity for reelin cleavage products (COS7 cells)                                                                                                                                             -- Δex7 only at E10 (total brain RNA)\                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                   -- +/Δex7 at E12 and E15/16 (total brain RNA)\                                                                                                                                               
                                                                                                                                                                                                                                                                                                                   -- E15/16: cerebrum contains +/Δex7 while cerebellum and olfactory bulbs soley express +ex7 (RNA)\                                                                                           
                                                                                                                                                                                                                                                                                                                   -- Ex7 cerebrum expression higher at E15-17 than P10 (protein)\                                                                                                                              
                                                                                                                                                                                                                                                                                                                   -- Ex7 cerebellar expression increases from E17 to P10 (protein)\                                                                                                                            
                                                                                                                                                                                                                                                                                                                   -- Cerebellum contains higher ex7 levels than cerebrum at P10 (protein)\                                                                                                                     
                                                                                                                                                                                                                                                                                                                   -- P10 cerebellum: ex7 expression in internal granule cell layer but not external granule layer or Purkinje cells (protein)\                                                                 
                                                                                                                                                                                                                                                                                                                   -- E17 ex7 expression in cortical plate, but scarce in Marginal, Intermediate and Subventricular zones (protein)\                                                                            

  Murine exon 7B\           Furin cleavage site                                        -- Cleaved in furin dependent manner (HEK-293 cells)\                                                                             Cleavage product remains undetected in brain                                              **Murine**:\                                                                                                                                               Preliminary evidence for Rbfox2   [@B6], [@B5]; [@B35]; [@B19]
  (Human exon 6B)                                                                      -- Extracellular cleavage product binds reelin\                                                                                                                                                                             -- low level inclusion of ex7B (total adult and embryonic brain RNA)\                                                                                                                        
                                                                                       -- Cleavage product suppresses Dab1 phosphorylation (primary neurons IP)                                                                                                                                                    -- mutually exclusive with ex7 (total brain RNA)\                                                                                                                                            
                                                                                                                                                                                                                                                                                                                   -- low level inclusion of ex7B in E15-16 cerebrum but none in E15-16 cerebellum or olfactory bulb (RNA)\                                                                                     
                                                                                                                                                                                                                                                                                                                   **Human**:\                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                   -- low level inclusion of ex6B (total brain RNA)\                                                                                                                                            

  Murine exon 16\           O-linked glycosylation site; extracellular cleavage site   -- Required for extracellular cleavage by metalloproteases (HEK-293 cells and primary neurons)\                                   **Murine:**\                                                                              **Human**:\                                                                                                                                                Unknown                           [@B9]; [@B51]
  (Human exon 15)                                                                      -- Required for receptor sugar glycosylation (CHO cells and brain lysate)\                                                        **Constitutive exclusion leads to**:\                                                     -- +/Δex15 both detected in adult frontal cortex, hippocampus and cerebellum and fetal brain (RNA)\                                                                                          
                                                                                       -- Exclusion alters hippocampal LTP and CA1 synaptic strength in exon 19 dependent manner (hippocampal slice electrophysiology)   -- increased brain apoER2 mRNA and protein levels\                                                                                                                                                                                                                                     
                                                                                                                                                                                                                         -- increase in hippocampal dendritic spines\                                                                                                                                                                                                                                           
                                                                                                                                                                                                                         -- impaired fear acquisition (context and cued fear conditioning task)\                                                                                                                                                                                                                
                                                                                                                                                                                                                         -- augmented glutamate receptor expression                                                                                                                                                                                                                                             

  Murine exon 19\           Cytoplasmic insert                                         -- Binds adaptor proteins JIP1, JIP2, PSD-95, APBA1, APBA2 (Y2H screen, IP)\                                                      **Murine**:\                                                                              **Murine**:\                                                                                                                                               -- Moderate evidence for SRSF1\   [@B34]; [@B9]; [@B47]; [@B20]; [@B4]; [@B3]; [@B23]; [@B25]
  (Human exon 18)                                                                      -- Required for reelin-induced LTP in hippocampus (hippocampal slice electrophysiology)                                           Ex19 inclusion lower in aging and amyloid mouse model hippocampus (semi-qRT-PCR)\         -- brain stem cells solely express Δex19\                                                                                                                  -- Activity regulated             
                                                                                                                                                                                                                         **Constitutive exclusion confers**:\                                                      -- approximately equal +/Δex19 levels found in primary neurons, total brain RNA and hippocampal RNA\                                                                                         
                                                                                                                                                                                                                         -- deficits in hippocampal dependent learning (fear conditioning/associative learning)\   -- ex19 confirmed at protein level (total brain lysate)\                                                                                                                                     
                                                                                                                                                                                                                         -- decreased number of adult corticospinal neurons\                                       **Human:**\                                                                                                                                                                                  
                                                                                                                                                                                                                         -- decreased thickness of adult primary motor cortex\                                     -- approximately equal +/Δex18 levels in adult middle temporal region, frontal cortex, hippocampus and cerebellum and whole fetal and adult brains (RNA)                                     
                                                                                                                                                                                                                         -- protection from corticospinal neuronal death following brain injury\                                                                                                                                                                                                                
                                                                                                                                                                                                                         **Human**:\                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                         -- Ex18 inclusion is lower in middle temporal region of the AD brain (semi-qRT-PCR)\                                                                                                                                                                                                   
                                                                                                                                                                                                                         -- Ex18 inclusion associated with global cognition (linear regression models)\                                                                                                                                                                                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LDLa, Low density lipoprotein receptor class A; HEK-293, Human Embryonic Kidney-293; VLDL, Very low density lipoprotein; IP, immunoprecipitation; LTP, Long term potentiation; Y2H, Yeast-2-Hybrid; qRT-PCR, quantitative real time-polymerase chain reaction.

Human and Murine Exon 5 and Murine Exon 7 {#S3.SS1}
-----------------------------------------

Exon 5 (ex5) encodes LDLa binding repeats 4--6. In the murine brain, ex5 is constitutively excluded ([@B5]). In humans, ex5 is included approximately 50% of the time in total brain RNA ([@B33]), yet is absent in RNA from fetal brain and adult frontal cortex, hippocampus and cerebellum ([@B9]), suggesting ex5 splicing is under spatiotemporal regulation. Functionally, exclusion of ex5 prevents apoER2 from binding α~2~-macroglobulin ([@B5]), a secreted protein that inhibits proteases and sequesters ligands ([@B7]). Murine variants lacking both exons 5 and 7 have lower affinity for β-VLDL *in vitro* compared to those lacking ex5 alone ([@B5]), which could regulate lipid trafficking.

Apolipoprotein E receptor 2 also binds secreted glycoprotein Reelin ([@B11]), which regulates neuronal migration ([@B49]) and long-term potentiation (LTP) ([@B52]). Reelin-apoER2 binding occurs primarily between the first apoER2 LDLa repeat encoded by exon 2 ([@B54]) and the Reelin central fragment consisting of reelin repeats 3--6 ([@B30]). This affinity can be tuned both by alternative splicing of apoER2 and proteolytic cleavage of Reelin. Exclusion of the eighth LDLa repeat, encoded by exon 7 (ex7), increases apoER2's affinity for Reelin fragments in which Reelin repeats 7--8 are cleaved from the central fragment. The eighth LDLa repeat sterically hinders binding of the Reelin central fragment, thereby modulating apoER2-Reelin affinity and subsequent signaling ([@B24]).

Interestingly, murine ex7 expression overlaps with neuronal migration ([Table 1](#T1){ref-type="table"}), suggesting the eighth LDLa repeat can modulate network formation or synaptic plasticity ([@B24]). However, this possibility has yet to be tested. As the eighth LDLa repeat is not present in human APOER2 ([@B34]), how this functionally translates to humans is unclear. The regulatory mechanisms controlling ex5 and ex7 splicing are also unknown.

Human Exon 6B (Murine Exon 7B) {#S3.SS2}
------------------------------

Human exon 6B encodes thirteen amino acids in the APOER2 extracellular domain including the furin consensus sequence RXXR. In the murine brain, exon 7B (ex7B) inclusion is only observed when ex7 is excluded ([@B6], [@B5]). *In vitro*, murine isoforms containing ex7B are proteolytically cleaved in a furin-dependent manner releasing a soluble extracellular product. This furin-cleaved product acts as a dominant-negative inhibitor of full-length apoER2 by binding and sequestering Reelin, therefore interfering with Reelin-apoER2 signaling. Although the soluble fragment has yet to be identified *in vivo*, it may be present at low concentrations and contribute to Reelin pathway modulation. Ex7B also appears to be developmentally regulated, as it is detectable in the cortex but not the olfactory bulb or cerebellum in murine E15-16 brains ([@B35]).

Splicing factor Rbfox2 has been identified as a possible regulator of murine ex7B splicing. In *Rbfox2*^--/--^ mice, brain apoER2 ex7B inclusion is increased compared to wild-type mice, suggesting Rbfox2 may serve as a repressor of ex7B inclusion. Five potential Rbfox2 binding sites near ex7B were identified, of which three are conserved across species ([@B19]). To confirm Rbfox2 directly modulates ex7B inclusion, binding of Rbfox2 to apoER2 putative binding sites still needs to be demonstrated.

Human Exon 18 (Murine Exon 19) {#S3.SS3}
------------------------------

Human exon 18 (ex18) encodes the APOER2 cytoplasmic insert. In adult mice, exon 19 (ex19) is essential for Reelin-induced enhancement of hippocampal LTP ([@B4]). The encoded cytoplasmic insert binds postsynaptic density protein-95 (PSD-95) ([@B20]), which recruits Src family kinases to phosphorylate NMDA receptor subunits. This increases calcium conductance, facilitating LTP ([@B4]; [@B8]). Accordingly, mice constitutively lacking ex19 (Δex19) demonstrate deficits in hippocampal-dependent learning. As Δex19 mice show no neuroanatomical changes, this learning deficit is likely due to loss of the functional apoER2-NMDA receptor complex, not altered neuronal migration ([@B4]).

Murine ex19 alternative splicing is also involved in neural degeneration and aging, as adult Δex19 mice have fewer corticospinal neurons and a thinner primary motor cortex. Interestingly, in response to brain injury, Δex19 mice are protected from neuronal death compared to wild-type and constitutively expressing ex19 (+ex19) mice. This effect is likely due to ex19-dependent binding of JNK-interaction proteins 1 and 2 (JIP1, JIP2) ([@B20]; [@B47]), which activate Jun N-terminal kinase (JNK) and cellular death signaling ([@B3]). Ex19 also interacts with neuronal adaptor proteins X11α and X11β, officially APBA1 and 2 ([@B23]). ApoER2-APBA1/2 binding facilitates formation of a protein complex containing BACE1 and amyloid precursor protein (APP). ApoE-apoER2 binding promotes APBA1/2-dependent endocytosis of APP and BACE1 leading to Aβ production ([@B23]), a neuropathological hallmark of AD. However, whether the apoER2-APBA1/2 interaction affects Aβ production *in vivo* remains to be determined. Interestingly, Reelin decreases apoER2-APBA1/2 interaction in neurons ([@B40]), suggesting that Reelin and apoE binding to apoER2 modulates intracellular adaptor protein interaction and functions.

In humans, ex18 inclusion is positively correlated with global cognition. AD patients demonstrate lower apoER2 ex18 inclusion in the middle temporal cortex compared to non-cognitively impaired patients. Murine ex19 inclusion is also decreased in the hippocampus of AD mouse model TgCRND8 (APP carrying Swedish and Indiana mutations) and increasing ex19 inclusion with antisense oligonucleotides (ASOs) can partially rescue hippocampal-dependent spatial learning ([@B25]). It is therefore reasonable to hypothesize that apoER2 alternative splicing manipulation could be therapeutically useful for AD, especially considering the success of other ASOs in neurodegenerative diseases ([@B53]).

Due to apoER2's role in memory, understanding ex18 splicing regulation is critical. *Lrp8* contains two putative binding sites in the flanking 3′-intron of ex18 for serine/arginine-rich splicing factor 1 (SRSF1) that are conserved across humans and mice. Knockdown of SRSF1 or application of an ASO targeting SRSF1 binding sites increases ex18 inclusion, suggesting SRSF1 represses ex18 inclusion ([@B25]). However, it is unclear whether the ASO-induced increase in ex18 inclusion is dependent on SRSF1. Periods of activity also regulate ex19 in the murine brain, with higher inclusion during periods of feeding and lower inclusion during less active periods ([@B4]). Exactly how regulation occurs during periods of activity and whether it involves SRSF1 is unknown.

Human Exon 15 (Murine Exon 16) {#S3.SS4}
------------------------------

Human exon 15 encodes the O-linked sugar domain of APOER2, the site of O- and N-linked glycosylation. This region contains an extracellular cleavage site for matrix metalloproteinases (MMPs), like ADAM10, as murine exon 16 (ex16) exclusion prevents apoER2 cleavage ([@B51]). Reelin-apoER2 binding stimulates MMP cleavage of the receptor followed by a second intramembranous cleavage by γ-secretase. This releases the intracellular domain (ICD) which translocates to the nucleus and activates an enhancer profile necessary for transcription of learning and memory genes ([@B48]). As ex16 encodes the MMP cleavage site, ex16 inclusion regulates the apoER2 proteolytic pathway and likely ICD translocation. However, a conclusive link between ex16 inclusion and ICD translocation has yet to be established. Of note, the ICD contains the cytoplasmic insert encoded by ex19, which could affect enhancer activation.

Constitutive ex16 exclusion (Δex16) confers higher apoER2 levels in the murine brain, both at the protein and mRNA level. Tandem deletion of ex19 (Δex16/Δex19) in mice exacerbates this effect ([@B51]), suggesting that apoER2 splicing impacts total apoER2 expression. Precise control of apoER2 expression is critical, as overexpression and knockout lead to increases and decreases, respectively, in dendritic spines, suggesting that apoER2 affects synapse formation ([@B13]). Synaptic apoER2 levels are also post-translationally regulated by E3 ubiquitin ligase Inducible Degrader of the LDL receptor (IDOL). Neuronal activity downregulates IDOL, allowing apoER2 levels to increase and initiate cytoskeletal remodeling and LTP through induction of the GTPase Rac1. ApoER2's binding of JIP1/2 may modulate Rac1 activation as JIP1/2 also bind Tiam1, the guanine nucleotide exchange factor that ties NMDAR to Rac1 activation ([@B18]). While IDOL ubiquitinates apoER2 within constitutive murine exon 18, JIP1/2 binds the cytoplasmic insert ([@B47]), suggesting that alternative splicing may influence this pathway.

Due to elevated apoER2 levels, Δex16 mice display increased CA1 hippocampal spine numbers yet weaker synapses. Tandem exclusion of ex19 exacerbates both phenotypes. While Δex16/Δex19 mice show the larger increase in apoER2 expression and spine numbers, it is Δex16 mice constitutively expressing ex19 (Δex16/+ex19) that show augmented LTP compared to wild-type. As this difference can be rescued by reducing apoER2 expression ([@B51]), it is curious that Δex16/Δex19 mice do not demonstrate a similar or stronger LTP response. This is also intriguing given +ex19 mice alone show no LTP or synaptic strength alterations ([@B4]), suggesting for the first time *in vivo* that tandem apoER2 splicing events can have unique synaptic effects. To parse out which effects depend on ex16 or ex19, a study that compares mice with individual and double exon manipulations would be beneficial.

Exclusion of ex16 impairs murine fear acquisition, with the effect again modulated by ex19 inclusion and rescued by reducing apoER2 levels ([@B51]). Δex16/Δex19 mice demonstrate increased glutamate receptor subunit expression of AMPARs and NMDARs as well. This is likely due to the increased apoER2 protein observed, as apoER2 binds NMDA subunits extracellularly ([@B26]) and increases dendritic spine numbers ([@B51]). The mechanisms regulating ex16 splicing, and if they co-regulate ex19 splicing, remain to be determined.

Additional APOER2 Splicing Events {#S3.SS5}
---------------------------------

Several additional *APOER2* exons are alternatively spliced in the human brain, such as exon 6 (LDLa repeat 7) and exons 7 and 8 (EGF repeats) ([@B6]; [@B33]; [@B9]; [@B41]). However, the functional properties of these mRNAs are unknown. In humans, there is a 73-nucleotide insertion sometimes included between exons 7 and 8 that introduces a frame-shift and early stop codon and is observed in the fetal but not adult brain ([@B6]; [@B9]). These events are also observed in combination, such as exclusion of both human exons 5 and 6 ([@B32]) and exclusion of both human exons 5 and 8 ([@B9]). Despite the identification of these splicing events over 20 years ago, their effect on apoER2 function remains to be determined.

APOER2 Transcript Stability {#S4}
===========================

RNA-binding proteins also affect apoER2 transcript stability. The RBP SRSF11 is downregulated in aged murine and primate prefrontal cortex and induces age-associated decline, partly through modulating apoER2 expression. SRSF11 binds directly to the 3′-UTR of *apoER2*, enhancing transcript stability. Interestingly, SRSF11 binding also regulates *apoE* mRNA stability. ApoE and apoER2 levels modulate JNK pathway activation and age-related neuronal loss, making SRSF11 a key RBP in the aging brain ([@B43]). It remains to be seen whether apoER2 alternative splicing is involved in the SRSF11-apoER2-JNK pathway, although it seems likely as apoER2 ex19 is required for apoER2-JIP1/2 interaction ([@B3]). The mechanism underlying decreased SRSF11 expression in aging is also unclear. The roles of SRSF11, SRSF1 and Rbfox2 highlight how multiple RBPs must be regulated to exert a concerted effort on apoER2 splicing and expression levels, which are also affected by apoER2 isoforms themselves.

Conclusion and Future Perspectives {#S5}
==================================

Overall, it is clear that alternative splicing modulates apoER2 synaptic function in the adult and aging brain. However, the function of apoER2 alternative splicing in brain development is less defined. ApoER2 ex7B, for example, is well placed to modulate neuronal migration due to its expression profile ([Table 1](#T1){ref-type="table"}; [@B35]) and the importance of implicated regulator Rbfox2 in cerebellar development ([@B19]). Investigating apoER2 alternative splicing during development will require precise manipulation of exon inclusion through techniques such as splice site switching ASOs, RNA-guided dCas9 ([@B36]) and targeted mouse genetics. Our current understanding of apoER2 alternative splicing is limited by the incomplete spatiotemporal characterization of each isoform. Future studies evaluating apoER2 variants must be quantitative, robust and include multiple time points and brain regions.

Advances in single-cell technology and sequencing have highlighted the importance of alternative splicing in defining neuronal subtypes. Recent data from ribosome-engaged transcript profiling in genetically defined murine forebrain neurons have revealed that apoER2 alternative splicing may be partially subtype specific. Additional apoER2 alternative splicing events were identified, including alternative 5′- and 3′-splice acceptor sites, intron retention and alternative transcriptional start sites, suggesting multiple levels of alternative splicing complexity regulate apoER2 ([@B17]). Traditional approaches like qRT-PCR can be coupled with electrophysiology to match cell-type specific firing properties with possible cell-type specific alternative splicing events. Furthermore, recent technological advances like BaseScope ultra-sensitive *in situ* hybridization ([@B15]) enable isoform localization *in vivo*. This level of cell-type specificity must become a pillar in the splicing field to truly grasp alternative splicing intricacy.

Establishing cell-type alternative splicing patterns will also help identify RBPs that regulate apoER2 splicing events in those subtypes. Numerous technologies are available to identify apoER2 RNA-RBP interactions, often incorporating unbiased mass spectrometry ([@B46]). Beyond the effect of RBPs on alternative splicing of individual apoER2 exons, regulatory pathways and epigenetic factors modulating RBPs are another layer of complexity that must be understood. Furthermore, human alternative splicing regulation must be investigated dynamically, likely in stem cell-derived induced-neurons ([@B56]).

Moving forward, the role of synaptic modulators like apoER2 will only be understood in physiological and disease states once distribution, function and regulation of all their isoforms is defined. From there, perhaps targeted manipulation of the splicing code can provide future therapeutic interventions. ASOs have shown therapeutic efficacy in correcting pathogenic splicing deficits, such as Nusinersen 1 in spinal muscular atrophy ([@B53]). Interfering with the spliceosome or splicing factors themselves using small molecules offers another potential intervention point, although less specific. This strategy is being utilized in cancer research and has helped define splicing regulatory pathways ([@B14]). Overall, defining the splicing code for both apoER2 and other synaptic proteins is the next frontier for understanding how the brain develops, matures and ages.
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